25. Furman has not directed us to corroboration for much of Dr. Furman's testimony.
Dr. Liotta's smples:
26. Furman has submitted evidence that appears to be a letter from Dr. Liotta to the F 'Iman
inventors. (Exh. 2038).
27. The letter, dated 3 November 1989, states as follows:
As you know, we have recently developed a number of novel approaches
for synthesizing antiviral nucleosides. In the course of our studies, we have
prepared a number of novel nucleosides which, to our knowledge, have never
been tested for their antiviral activity. It would be very helpM to us if you could
evaluate these materials in your antiviral screens. If you are interested in pursuing
this matter, would you please arrange to have a testing agreement sent to me so
that we can initiate this matter?
28. Furman has submitted evidence that appears to be a letter from Dr. Liotta to Dr. Painter.
(Exh. 2039).
29. The letter, dated 18 July 1990, states as follows:
I was glad to hear that all the legal details between Wellcome and Emory have
finally been resolved. As a consequence, I am pleased to be able to send you
sixteen samples to be evaluated for antiviral activity. In accord with our
conversations on the matter, I have coded the compounds as DCL-01 through
DCL-16 (see attached sheet). I look forward to hearing the outcome of the
bioassays.
30, Furman has submitted evidence that appears to be a research agreement between BW and
Emory University, (Exh. 2040). The agreement states, inter jilia, that:
14
Page: Previous 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next
Last modified: November 3, 2007